Invesco Ltd. Summit Therapeutics Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Invesco Ltd. holds 74,495 shares of SMMT stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,495

Previous 71,677 3.93%

Holding current value

$1.33 Million

Previous $559,000 191.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$6.89 - $31.93 $19,416 - $89,978	2,818 Added 3.93%	74,495 $1.63 Million
Q2 2024 Aug 13, 2024	SELL	$2.39 - $10.92 $9,082 - $41,496	-3,800 Reduced 5.03%	71,677 $559,000
Q1 2024 May 14, 2024	BUY	$2.55 - $5.07 $13,892 - $27,621	5,448 Added 7.78%	75,477 $312,000
Q4 2023 Feb 12, 2024	SELL	$1.67 - $2.83 $9,301 - $15,763	-5,570 Reduced 7.37%	70,029 $182,000
Q3 2023 Nov 13, 2023	BUY	$1.54 - $2.42 $817 - $1,285	531 Added 0.71%	75,599 $141,000
Q2 2023 Aug 11, 2023	BUY	$1.32 - $2.81 $81,950 - $174,456	62,084 Added 478.16%	75,068 $188,000
Q1 2023 May 12, 2023	BUY	$1.38 - $5.41 $17,917 - $70,243	12,984 New	12,984 $22,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $10,371 - $26,829	-11,273 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.0 - $3.45 $1,168 - $2,014	584 Added 5.46%	11,273 $28,000
Q4 2021 Feb 14, 2022	SELL	$2.45 - $5.64 $20,771 - $47,815	-8,478 Reduced 44.23%	10,689 $28,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $8.27 $14,625 - $25,041	3,028 Added 18.76%	19,167 $96,000
Q2 2021 Aug 17, 2021	BUY	$5.15 - $8.46 $83,115 - $136,535	16,139 New	16,139 $120,000

Others Institutions Holding SMMT

# of Institutions

192

Shares Held

75.8M

Call Options Held

2.01M

Put Options Held

2.84M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.6B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account